Drilldown: Medicines
Medicines > classes 
:
Research material or
[[:Category:Acetic_acid_derivatives|Acetic acid derivative]]
& routes:
Oral
:
Research material or
[[:Category:Acetic_acid_derivatives|Acetic acid derivative]]
& routes:
Oral Use the filters below to narrow your results.
generic:
brand:
classes: (Click arrow to add another value)
mechanism:
Positive allosteric modulator of the GABA<sub>A</sub> receptor at the benzodiazepine binding site; increases frequency of Cl<sup>−</sup> channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects. (1) ·
'"`UNIQ--vote-000011F4-QINU`"' Like all NSAIDs, raises CV thrombotic risk modestly (FDA 2014/2015 advisory) and produces GI, renal, hypertensive, and platelet-inhibitory effects characteristic of the class'"`UNIQ--ref-000011F5-QINU`"'. (1)
uses:
starting dose:
preparations:
fda max:
routes: (Click arrow to add another value)
onset:
halflife:
bioavailability:
pregnancy:
Avoid after 20 weeks (NSAID-class FDA 2020 advisory on fetal renal injury and oligohydramnios with second/third-trimester use).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1)
Showing below up to 2 results in range #1 to #2.